A systematic review of four studies found semaglutide significantly improved quality of life, walking distance, body weight, inflammation, and reduced major cardiovascular events by 24% in heart failure patients.
24% reduction in major cardiac eventsHazard ratio of 0.76 (95% CI 0.62–0.92) for MACE in heart failure patients treated with semaglutide versus controls
What the researchers found
Four studies (3 RCTs + 1 observational study) examining semaglutide in heart failure patients found statistically significant improvements in:
- Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score (P<0.001) — measuring quality of life and symptom burden
- Body weight reduction (P<0.001)
- Six-minute walk distance (P<0.001) — measuring exercise capacity
- C-reactive protein (CRP) levels (P<0.001) — measuring systemic inflammation
- Major adverse cardiac events: HR = 0.76 (95% CI: 0.62–0.92) — a 24% risk reduction
Adverse effects were observed but were not significantly worse than placebo.
Why it matters
Heart failure affects approximately 64 million people worldwide and remains a leading cause of hospitalization and death. Current treatments improve survival but many patients continue to have debilitating symptoms and poor quality of life. Semaglutide's ability to simultaneously improve symptoms (KCCQ scores), functional capacity (walking distance), inflammation (CRP), and hard outcomes (MACE) makes it potentially transformative — addressing multiple aspects of heart failure that existing treatments may not fully cover.
How the study worked
A systematic review was performed searching PubMed/Medline, the Cochrane Library, and Google Scholar through May 10, 2024. Studies meeting inclusion criteria were selected, yielding four eligible studies: three randomized controlled trials and one observational study. Qualitative analysis synthesized findings across studies for quality of life, body weight, exercise capacity, inflammation, cardiovascular events, and adverse effects.
What this study cannot tell us
Only four studies were included, limiting the breadth of evidence. The mix of RCTs and observational studies introduces heterogeneity. A qualitative rather than quantitative meta-analysis was performed, so pooled effect sizes may not be available. The specific heart failure subtypes (HFpEF vs HFrEF), semaglutide doses, and treatment durations across the four studies are not detailed in the abstract. Publication in Cureus suggests a lower-impact venue for the systematic review itself, though the included trials were published in high-impact journals. Long-term safety of semaglutide in heart failure beyond the trial periods is unknown.
How to read the evidence
This systematic review includes three RCTs and one observational study, providing moderate-quality evidence. The consistent significance across multiple endpoints (all P<0.001) is compelling. However, only four studies were available, and qualitative rather than quantitative synthesis was performed. The underlying RCTs provide the strongest individual evidence.
When this study was published
Published in 2024 with a search through May 2024, this review captures the emerging evidence from the STEP-HFpEF program and related trials. Additional heart failure trials with GLP-1 agonists are ongoing.
The bigger picture
This systematic review arrives at a pivotal moment for GLP-1 drugs in cardiology. The STEP-HFpEF trials demonstrated semaglutide's benefits specifically in heart failure with preserved ejection fraction (HFpEF) — a condition that previously had almost no effective treatments. Combined with the SELECT trial showing cardiovascular risk reduction in obesity, these findings are establishing GLP-1 agonists as important cardiovascular drugs, not just diabetes medications. This represents one of the most significant expansions of a drug class's therapeutic scope in decades.
Questions still open
- Should semaglutide be considered a standard treatment for heart failure with preserved ejection fraction (HFpEF)?
- Does semaglutide's heart failure benefit extend to patients without diabetes or obesity?
- Which specific mechanism — weight loss, anti-inflammation, or direct cardiac effects — drives the improvement in heart failure outcomes?
Common questions
How does semaglutide help with heart failure when it's primarily known as a diabetes drug?
What does the KCCQ score measure and why does it matter?
Read the original research
Semaglutide in Heart Failure: A Systematic Review of Outcomes of Semaglutide in Heart Failure Patients.
Cureus, 16(7), e64668
Citation
Gupta, Nishtha; Uwawah, Tesingin D; Singh, Kamaldeep; Madan, Hritik; Kumar, Siddharth; Midha, Bharat; Soni, Kriti; Singh, Aparjit; Bhogal, Amandeep; Jain, Arpit. (2024). Semaglutide in Heart Failure: A Systematic Review of Outcomes of Semaglutide in Heart Failure Patients.. Cureus, 16(7), e64668. https://doi.org/10.7759/cureus.64668